Add Yahoo as a preferred source to see more of our stories on Google. Part B aims to expand clinical indications for OCS Heart to include standard criteria DBD hearts transplanted within four hours.
The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...
TransMedics TMDX recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its next-generation OCS ENHANCE Heart trial, eliminating a key ...
TransMedics Group has received full and unconditional investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) for its next-generation OCS ENHANCE Heart trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results